Why Wall Street is unfazed by Medicare drug pricing threat [Video] – AOL
Wall Street concerns about anti-inflation price negotiations for the first 10 drugs in Medicare Part D plans appear to be fading. As the Sept. 1 announcement date approaches, executives at big pharmaceutical companies are signaling they are open to any eventual price cuts set by the federal government. On earnings calls in the past few […]